Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

54 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The Effect of Age and Other Patient Characteristics on Outcomes Among Nontransplanted Patients Who Were Treated With First-Line Lenalidomide, Bortezomib, and Dexamethasone: Results From the ConnectⓇ MM Registry.
Abonour R, Lee HC, Rifkin R, Ailawadhi S, Omel J, Hardin JW, Narang M, Toomey K, Gasparetto C, Wagner LI, Terebelo H, Mouro J, Dhanasiri S, Liu L, Yu E, Jagannath S. Abonour R, et al. Among authors: terebelo h. Clin Lymphoma Myeloma Leuk. 2024 Oct;24(10):e336-e343. doi: 10.1016/j.clml.2024.05.021. Epub 2024 Jun 3. Clin Lymphoma Myeloma Leuk. 2024. PMID: 39033038
Treatment Patterns, Survival, Quality of Life, and Healthcare Resource Use Among Patients With Triple-Class Refractory Multiple Myeloma in US Clinical Practice: Findings From the Connect MM Disease Registry.
Lee HC, Ramasamy K, Weisel K, Abonour R, Hardin JW, Rifkin RM, Ailawadhi S, Terebelo HR, Durie BGM, Tang D, Joshi P, Liu L, Jou YM, Che M, Hernandez G, Narang M, Toomey K, Gasparetto C, Wagner LI, Jagannath S. Lee HC, et al. Among authors: terebelo hr. Clin Lymphoma Myeloma Leuk. 2023 Feb;23(2):112-122. doi: 10.1016/j.clml.2022.11.008. Epub 2022 Nov 23. Clin Lymphoma Myeloma Leuk. 2023. PMID: 36567211 Free article.
Real-World Utilization of Radiation Therapy in Multiple Myeloma: An Analysis of the Connect MM Registry.
Ballas L, Ailawadhi S, Narang M, Gasparetto CJ, Lee HC, Hardin JW, Durie BGM, Toomey K, Omel J, Wagner LI, Abonour R, Terebelo HR, Joshi P, Yu E, Liu L, Rifkin RM, Jagannath S. Ballas L, et al. Among authors: terebelo hr. Pract Radiat Oncol. 2024 Mar-Apr;14(2):e141-e149. doi: 10.1016/j.prro.2023.11.004. Epub 2023 Nov 19. Pract Radiat Oncol. 2024. PMID: 37984714
Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS.
Moreau P, Chari A, Oriol A, Martinez-Lopez J, Haenel M, Touzeau C, Ailawadhi S, Besemer B, de la Rubia Comos J, Encinas C, Mateos MV, Salwender H, Rodriguez-Otero P, Hulin C, Karlin L, Sureda Balari A, Bargay J, Benboubker L, Rosiñol L, Tarantolo S, Terebelo H, Yang S, Wang J, Nnane I, Qi M, Kosh M, Delioukina M, Goldschmidt H. Moreau P, et al. Among authors: terebelo h. Blood Cancer J. 2023 Mar 7;13(1):33. doi: 10.1038/s41408-023-00805-x. Blood Cancer J. 2023. PMID: 36882409 Free PMC article. No abstract available.
Efficacy and Safety of Pacritinib vs Placebo for Patients With Severe COVID-19: A Phase 2 Randomized Clinical Trial.
Cafardi J, Miller C, Terebelo H, Tewell C, Benzaquen S, Park D, Egan P, Lebovic D, Pettit K, Whitman E, Tremblay D, Feld J, Buckley S, Roman-Torres K, Smith J, Craig A, Mascarenhas J. Cafardi J, et al. Among authors: terebelo h. JAMA Netw Open. 2022 Dec 1;5(12):e2242918. doi: 10.1001/jamanetworkopen.2022.42918. JAMA Netw Open. 2022. PMID: 36469321 Free PMC article. Clinical Trial.
Impact of lenalidomide-bortezomib-dexamethasone induction on patients with newly diagnosed multiple myeloma and renal impairment: Results from the Connect® MM Registry.
Ailawadhi S, Lee HC, Omel J, Toomey K, Hardin JW, Gasparetto CJ, Jagannath S, Rifkin RM, Durie BGM, Narang M, Terebelo HR, Joshi P, Jou YM, Mouro J, Yu E, Abonour R. Ailawadhi S, et al. Among authors: terebelo hr. Blood Cancer J. 2024 Nov 11;14(1):198. doi: 10.1038/s41408-024-01177-6. Blood Cancer J. 2024. PMID: 39528478 Free PMC article.
OUTREACH: Phase 2 study of lisocabtagene maraleucel as outpatient or inpatient treatment at community sites for R/R LBCL.
Linhares Y, Freytes CO, Cherry M, Bachier C, Maris MB, Hoda D, Varela JC, Bellomo C, Cross S, Essell JH, Fanning S, Terebelo H, Yimer HA, Courtright J, Sharman JP, Kostic A, Vedal M, Ogasawara K, Avilion A, Espinola R, Yuan B, Mattar B. Linhares Y, et al. Among authors: terebelo h. Blood Adv. 2024 Sep 30:bloodadvances.2024013254. doi: 10.1182/bloodadvances.2024013254. Online ahead of print. Blood Adv. 2024. PMID: 39347584
Effect of t (11;14) Abnormality on Outcomes of Patients With Newly Diagnosed Multiple Myeloma in the Connect MM Registry.
Gasparetto C, Jagannath S, Rifkin RM, Durie BGM, Narang M, Terebelo HR, Toomey K, Hardin JW, Wagner L, Ailawadhi S, Omel JL, Srinivasan S, Dhalla M, Catamero D, Kitali A, Agarwal A, Abonour R; Connect MM Registry Investigators. Gasparetto C, et al. Among authors: terebelo hr. Clin Lymphoma Myeloma Leuk. 2022 Mar;22(3):149-157. doi: 10.1016/j.clml.2021.08.007. Epub 2021 Aug 29. Clin Lymphoma Myeloma Leuk. 2022. PMID: 34588149 Free article.
54 results